中文
  • About Us
    Corporate Overview Management Team Board of Directors Contact Us
  • Our Focus
    Viral Diseases NASH/PBC Cancer Exploratory Indications
  • Products&Pipeline
    Pipeline Products Clinical Trials
  • Partnership
  • Investors
    Financials & Filing Presentation Materials
  • News
  • Careers
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • Goldman Sachs Invests US$20 Million in Ascletis

    2015-12-03

  • Dr. Jinzi Wu was Invited to Speak at 11th Annual Gates Foundation Grand Challenges Conference

    2015-10-19

  • Ascletis Secures US$35 Million Financing

    2015-09-02

  • Ascletis Initiates Phase II Clinical Trial of Its Interferon-Free HCV Regimen in Taiwan

    2015-08-31

  • Ascletis as the First Chinese Company to File Clinical Applications for Interferon-Free HCV Treatment

    2015-06-24

  • HCV RACE IN CHINA

    2015-04-13

  • Ascletis’ triple therapy HCV drug nails phase II trial in Chinese patients

    2015-03-23

  • © 2018 Ascletis Pharma Inc.
  • 浙公网安备 33010802003344号
  • All Rights Reserved
  • 浙ICP备 11050387号-1

contact

  • pr@ascletis.com
  • bd@ascletis.com
  • hr@ascletis.com
  • clinicaltrials@ascletis.com

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号 浙ICP备11050387号-1